357,939 Shares in PROCEPT BioRobotics Corporation $PRCT Bought by Johnson & Johnson

Johnson & Johnson acquired a new position in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 357,939 shares of the company’s stock, valued at approximately $8,082,263. PROCEPT BioRobotics comprises about 0.0% of Johnson & Johnson’s holdings, making the stock its 11th largest holding. Johnson & Johnson owned approximately 0.63% of PROCEPT BioRobotics as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of PRCT. Prosight Management LP lifted its stake in PROCEPT BioRobotics by 1,692.4% in the fourth quarter. Prosight Management LP now owns 1,380,000 shares of the company’s stock valued at $43,415,000 after buying an additional 1,303,009 shares during the last quarter. Alliancebernstein L.P. grew its holdings in shares of PROCEPT BioRobotics by 58.6% in the 3rd quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock worth $122,052,000 after acquiring an additional 1,262,928 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its holdings in PROCEPT BioRobotics by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock worth $102,919,000 after purchasing an additional 1,218,815 shares in the last quarter. UBS Group AG grew its holdings in shares of PROCEPT BioRobotics by 129.3% during the 3rd quarter. UBS Group AG now owns 944,545 shares of the company’s stock worth $33,711,000 after purchasing an additional 532,530 shares in the last quarter. Finally, Millennium Management LLC grew its holdings in PROCEPT BioRobotics by 690.0% during the 4th quarter. Millennium Management LLC now owns 383,137 shares of the company’s stock worth $12,053,000 after acquiring an additional 448,077 shares during the last quarter. 89.46% of the stock is owned by hedge funds and other institutional investors.

PROCEPT BioRobotics Price Performance

Shares of NASDAQ PRCT traded up $0.01 during mid-day trading on Friday, hitting $20.61. 236,370 shares of the stock were exchanged, compared to its average volume of 1,561,276. The company has a market cap of $1.18 billion, a P/E ratio of -10.62 and a beta of 0.89. The stock’s fifty day simple moving average is $20.34 and its two-hundred day simple moving average is $23.96. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.35 and a current ratio of 6.55. PROCEPT BioRobotics Corporation has a twelve month low of $16.67 and a twelve month high of $42.43.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The business had revenue of $94.50 million during the quarter, compared to analyst estimates of $92.77 million. During the same period in the prior year, the business posted ($0.35) EPS. The company’s revenue for the quarter was up 19.3% compared to the same quarter last year. As a group, analysts forecast that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current fiscal year.

Insider Transactions at PROCEPT BioRobotics

In related news, CEO Larry L. Wood acquired 23,900 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was bought at an average price of $20.85 per share, for a total transaction of $498,315.00. Following the acquisition, the chief executive officer directly owned 23,900 shares of the company’s stock, valued at $498,315. This represents a ? increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last 90 days, insiders sold 1,000 shares of company stock valued at $28,480. Insiders own 4.00% of the company’s stock.

PROCEPT BioRobotics News Summary

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Several law firms reminded investors that September 22, 2026 is the deadline to seek appointment as lead plaintiff in a securities class action covering purchases of PROCEPT shares from February 28, 2024, through February 25, 2026. The repeated notices largely restate the same lawsuit and deadline rather than indicate multiple new cases. Kaplan Fox class action deadline announcement
• Negative Sentiment: The complaint alleges that PROCEPT misled investors about demand for its robotic-procedure handpieces by using repeated late-quarter bulk discounts to pull forward sales, while excess customer inventory accumulated. The case also points to later disclosures involving weaker handpiece performance, field inventory optimization, and procedure data. If the allegations lead to damages or settlement costs, the company could face additional financial pressure and investor confidence could suffer. The allegations have not been proven in court. Hagens Berman PROCEPT securities fraud class action notice

Analyst Upgrades and Downgrades

A number of research firms have commented on PRCT. Weiss Ratings restated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research note on Friday, July 17th. Truist Financial set a $21.00 price target on PROCEPT BioRobotics in a research note on Wednesday, August 5th. TD Cowen reduced their target price on PROCEPT BioRobotics from $34.00 to $28.00 and set a “buy” rating on the stock in a report on Wednesday, August 5th. Wells Fargo & Company lowered PROCEPT BioRobotics from an “overweight” rating to an “equal weight” rating and set a $19.00 price target on the stock. in a research note on Wednesday, August 5th. Finally, William Blair cut PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, PROCEPT BioRobotics has an average rating of “Hold” and an average price target of $28.00.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.